{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:31:37Z","timestamp":1787315497750,"version":"build-2736575974"},"reference-count":32,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,4,15]]},"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:p>Neuromyelitis optica spectrum disorder (NMOSD) is an uncommon antibody-mediated disease of the central nervous system, often associated with aquaporin-4 antibodies (AQP4-Ab). NMOSD may present as a subacute myelopathy, progressing over days with MRI revealing a contiguous inflammatory lesion of the spinal cord, \u22653 vertebral segments, a longitudinally extensive transverse myelitis. We describe an unusual paraneoplastic form of AQP4-Ab NMOSD that developed in a patient with an advanced diffuse large B-cell lymphoma. The patient had an unusual hyperacute onset, reaching a clinical nadir within hours.<\/jats:p>","DOI":"10.1136\/bcr-2020-239389","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T12:26:04Z","timestamp":1620131164000},"page":"e239389","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Neuromyelitis optica spectrum disorder as a paraneoplastic syndrome: a rare and challenging diagnosis"],"prefix":"10.1136","volume":"14","author":[{"given":"Mukhtar","family":"Gibril","sequence":"first","affiliation":[{"name":"General Medicine, Morriston Hospital, Swansea, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Walters","sequence":"additional","affiliation":[{"name":"Neurology Department, Morriston Hospital, Swansea, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"key":"2025082723533941000_14.5.e239389.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70216-8"},{"key":"2025082723533941000_14.5.e239389.2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729"},{"key":"2025082723533941000_14.5.e239389.3","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.19-2-169"},{"key":"2025082723533941000_14.5.e239389.4","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1177\/1352458517731914","article-title":"Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies","volume":"24","author":"Sep\u00falveda","year":"2018","journal-title":"Mult Scler"},{"key":"2025082723533941000_14.5.e239389.5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-537506"},{"key":"2025082723533941000_14.5.e239389.6","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1046\/j.1474-7766.2002.00096.x","article-title":"What the general neurologist needs to know about the paraneoplastic syndromes","volume":"2","author":"Grant","year":"2002","journal-title":"Pract Neurol"},{"key":"2025082723533941000_14.5.e239389.7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.3.652"},{"key":"2025082723533941000_14.5.e239389.8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.42.10.1931"},{"key":"2025082723533941000_14.5.e239389.9","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/124.6.1138"},{"key":"2025082723533941000_14.5.e239389.10","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2003.025171"},{"key":"2025082723533941000_14.5.e239389.11","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2013-000778"},{"key":"2025082723533941000_14.5.e239389.12","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2010.224105"},{"key":"2025082723533941000_14.5.e239389.13","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2010.224105"},{"key":"2025082723533941000_14.5.e239389.14","unstructured":"De Angelis LM , Posner JB . Neurologic complications of cancer. 2nd edn. Oxford: Oxford University Press, 2009: 577\u2013608."},{"key":"2025082723533941000_14.5.e239389.15","unstructured":"Miller EB . Autoimmunity and lymphoma: a brief review. J Rheum Dis Treat;4:062."},{"key":"2025082723533941000_14.5.e239389.16","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24141"},{"key":"2025082723533941000_14.5.e239389.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.06.033"},{"key":"2025082723533941000_14.5.e239389.18","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2017-001845"},{"key":"2025082723533941000_14.5.e239389.19","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/87.4.639"},{"key":"2025082723533941000_14.5.e239389.20","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol"},{"key":"2025082723533941000_14.5.e239389.21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.8.2457.2457"},{"key":"2025082723533941000_14.5.e239389.22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40120-018-0101-4","article-title":"Only follow-up of memory B cells helps monitor rituximab administration to patients with neuromyelitis optica spectrum disorders","volume":"7","author":"Lebrun","year":"2018","journal-title":"Neurol Ther"},{"key":"2025082723533941000_14.5.e239389.23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh446"},{"key":"2025082723533941000_14.5.e239389.24","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1313.014"},{"key":"2025082723533941000_14.5.e239389.25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-735605"},{"key":"2025082723533941000_14.5.e239389.26","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1002\/art.38798","article-title":"Induction of interleukin-6 production by rituximab in human B cells","volume":"66","author":"Jones","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025082723533941000_14.5.e239389.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2010.12.011"},{"key":"2025082723533941000_14.5.e239389.28","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/RHU.0000000000000756","article-title":"Autoimmune sequelae following rituximab therapy: a review of the literature and potential immunologic mechanisms","volume":"24","author":"Kersh","year":"2018","journal-title":"J Clin Rheumatol"},{"key":"2025082723533941000_14.5.e239389.29","first-page":"2052","article-title":"Il-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)","volume":"119","author":"Jones","year":"2009","journal-title":"J Clin Invest"},{"key":"2025082723533941000_14.5.e239389.30","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-219903","article-title":"Heroin-induced acute myelopathy with extreme high levels of CSF glial fibrillar acidic protein indicating a toxic effect on astrocytes","volume":"2017","author":"Sveinsson","year":"2017","journal-title":"BMJ Case Rep"},{"key":"2025082723533941000_14.5.e239389.31","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2019-002194"},{"key":"2025082723533941000_14.5.e239389.32","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1001\/jamaneurol.2018.2605","article-title":"Unique gadolinium enhancement pattern in spinal dural arteriovenous fistulas","volume":"75","author":"Zalewski","year":"2018","journal-title":"JAMA Neurol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-239389","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:53:51Z","timestamp":1756364031000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-239389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5,4]]},"published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1136\/bcr-2020-239389"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-239389","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}